Zhai et al. [53] found that NLRP1 functioned downstream of the MAPK/ERK signaling and contributed to acquired targeted therapy resistance in human metastatic melanoma, which was consistent with our findings. This evidence concerns the gene NLRP1 and metastatic melanoma.